For example, loss of CDKN2A/B homozygosity is closely related to poor prognosis, especially in WHO grade III glioma with loss of CDKN2A/B homozygosity, where the prognosis is similar to WHO grade IV glioma. This evidence concerns the gene CDKN2A and central nervous system cancer.